Lantern Pharma Inc.
LTRN
$3.36
-$0.19-5.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 12.67% | 16.62% | -40.36% | -42.52% | -4.49% |
| Total Depreciation and Amortization | 1,144.19% | 1,178.05% | -68.82% | 1,194.59% | 22.86% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -162.75% | -83.28% | 321.86% | -164.47% | -85.94% |
| Change in Net Operating Assets | 226.62% | -96.76% | 49.37% | -17.19% | -144.39% |
| Cash from Operations | 24.15% | -42.60% | -17.32% | -54.54% | -44.51% |
| Capital Expenditure | 100.00% | 45.45% | 39.22% | 37.50% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1,916.58% | 684.93% | 1,220.44% | 188.96% | 56.74% |
| Cash from Investing | 1,877.93% | 682.40% | 1,245.55% | 193.61% | 55.80% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | 100.00% | -- | -- |
| Foreign Exchange rate Adjustments | 146.90% | 128.57% | -1,300.00% | 232.79% | 276.56% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 94.12% | 68.34% | 83.72% | -43.66% | -32.69% |